Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...
Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...
Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause various diseases. However, other approaches achieve the same effect without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results